Tag: GlobeNewswire

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, Nov. 02, 2026 (GLOBE NEWSWIRE) — NowVertical Group Inc. (TSXV: NOW) (the “Company” or “NowVertical”) is pleased to announce that, further to its news release dated October 20, 2026, the TSX Venture Exchange (the “TSXV”) has cleared the Personal Information Forms required in connection with the subscription by Teraz Fund (“Teraz”) for Units (as defined below) in the first tranche (the “First Tranche”) of the Company’s private placement offering for gross proceeds of $15,100,000 (the “Offering”). Accordingly, the 15,833,334 Units subscribed for by Teraz that closed in escrow (the “Escrowed Units”), together with the related subscription proceeds of $1,900,000, have been released from escrow.

Under the First Tranche, Teraz subscribed for 25,000,000 Units at a price of $0.12 per Unit for gross proceeds of $3,000,000. Each unit of the Company (each, a “Unit”) consists of one Class A subordinate voting share in the capital of the Company (each, a “Common Share”) and one-half of one Common Share purchase warrant (each whole warrant, a “Unit Warrant”). Each Unit Warrant entitles the holder to acquire one Common Share at an exercise price of $0.20 until October 20, 2028.

In connection with the release of the Escrowed Units, and consistent with the terms of the Offering, the Company will pay to Clarus Securities Inc. (the “Agent”) a cash commission of $95,000, being 5% of the gross proceeds from the Esrowed Units, and will issue to the Agent 1,108,333 broker warrants (the “Broker Warrants”), being 7% of the number of Escrowed Units. Each Broker Warrant entitles the Agent to acquire one Unit at an exercise price of $0.12 per Unit until October 20, 2028.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States or any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. No securities may be offered or sold to, or for the account or benefit of persons in the United States or to any U.S. persons or in any other jurisdiction in which such offer or sale would be unlawful absent registration under the U.S. Securities Act, and any applicable state securities laws or an exemption therefrom or qualification under the securities laws of such other jurisdiction or an exemption therefrom. “United States” and “U.S. persons” shall have the meaning given to them in Regulation S under the U.S. Securities Act.

About NowVertical Group Inc.

NowVertical is a global data and analytics company which helps clients transform data into tangible business value with AI, fast. Offering a comprehensive suite of solutions and services, the Company enables clients to quickly harness the full potential of their data, driving measurable outcomes and accelerating potential return on investment. Enterprises optimize decision-making, improve operational efficiency, and unlock long-term value from their data using the Company’s AI-infused first-party and third-party technologies. The Company’s scalable AI-infused delivery model enables the business to efficiently deliver data, analytics and AI solutions and services across industries and geographies.

Cautionary Statements

This news release may contain forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable securities laws which reflect the Company’s current expectations regarding future events. All statements in this news release that are not purely historical statements of fact are forward-looking statements. Although the Company believes that such statements are reasonable and reflect expectations of future developments and other factors which management believes to be reasonable and relevant, the Company can give no assurance that such expectations will prove to be correct. Forward-looking statements in this news release are based on various assumptions, including that the TSXV will provide final approval of the Offering and that the risk factors referred to below, collectively, do not have a material impact on the Company’s business, operations, revenues and/or results. Forward-looking statements are often, but not always, identified by the use of forward-looking words such as “may”, “should”, “will”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause future results, performance, or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by the forward-looking statements. Such risks include but are not limited to those risks discussed under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis and its other disclosure documents filed on its SEDAR+ profile at www.sedarplus.com. Forward-looking statements are provided for the purpose of providing information about management’s expectations, beliefs and plans relating to the future and are not guarantees of future performance and undue reliance should not be placed thereon, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the Company. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

All of the forward-looking statements contained in this news release are qualified by the foregoing cautionary statements, and there can be no guarantee that the results or developments that the Company anticipates will be realized or, even if substantially realized, that they will have the expected consequences or effects on the Company’s business, financial condition or results of operation. Unless otherwise noted or the context otherwise indicates, the forward-looking statements contained herein are provided as of the date hereof, and the Company does not intend, and does not assume any obligation, to update the forward-looking statements except as otherwise required by applicable law.

Further Information
For further details about NowVertical, please visit www.nowvertical.com or contact:

NowVertical Group Inc.
Andre Garber
Chief Executive Officer
Telephone: 647-947-0223
Email: IR@nowvertical.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Earnings Webcast and Conference Call Set for Monday, November 9, 2026 at 5:00 p.m. Eastern Time

Miami, FL, Nov. 02, 2026 (GLOBE NEWSWIRE) — MARA Holdings, Inc. (NASDAQ: MARA) (“MARA” or the “Company”), a leading digital energy and infrastructure company, will hold a webcast and conference call on Monday, November 9, 2026 at 5:00 p.m. Eastern Time to discuss its financial results for the quarter ended September 30, 2026. Financial results will be published in a shareholder letter prior to the call on the investor relations section of the Company’s website.

To register to participate in the conference call or to listen to the live audio webcast, please use this link. The webcast will also be broadcast live and available for replay via the investor relations section of the Company’s website.

Earnings Webcast and Conference Call Details
Date: Monday, November 9, 2026
Time: 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time)
Registration link: LINK

If you have any difficulty joining the conference call, please contact MARA’s investor relations team at ir@mara.com.

About MARA
MARA Holdings, Inc. (NASDAQ: MARA) is a global, energy-backed digital infrastructure enterprise. We acquire, develop, and operate scarce powered assets at scale, with 1.9 GW of energized capacity today across nearly 20 sites on 4 continents, and a clear path to approximately 4.8 GW. Our vertically integrated model spans power, land, and compute, designed to deliver the speed, certainty, and reliability that AI, HPC, cloud, and enterprise customers need. Backed by almost a decade of operating power-intensive compute at industrial scale, Bitcoin mining is our operating foundation, providing a source of flexibility and keeping sites operating and generating revenue while we develop higher-value infrastructure paths.

For more information, visit www.mara.com, or follow us on:

Twitter: @MARA
LinkedIn: www.linkedin.com/company/maraholdings
Facebook: www.facebook.com/MARAHoldings
Instagram: @maraholdingsinc

MARA Company Contact:
Telephone: 800-804-1690
Email: ir@mara.com

MARA Media Contact:

Email: mara-jf@joelefrank.com

The Partnership Brings Together Payroll Tax Calculation and Compliance to Expand in the U.S. Enterprise Market

AUSTIN, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) — Asure Software, Inc. (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management software and payroll tax management solutions, and Vertex, Inc. (NASDAQ:VERX), the Decision-to-Defense™ global indirect tax and compliance company, today announced a strategic partnership designed to deliver an improved payroll tax calculation and compliance offering to the U.S. enterprise market.

The partnership includes Vertex’s payroll tax calculation technology with Asure’s Payroll Tax Management infrastructure for tax filing, remittance, W-2 processing, agency notice management and interaction with thousands of federal, state and local taxing authorities.

For Asure, the agreement creates an important new distribution channel for its Payroll Tax Management business and provides an opportunity to expand Asure’s share of the U.S. payroll tax compliance market.

“This partnership has the potential to improve access to Asure Payroll Tax Management,” said Pat Goepel, Chairman and CEO of Asure Software. “Vertex has spent decades building sophisticated payroll tax calculation technology and relationships across the enterprise payroll ecosystem. Asure has built the infrastructure which sits along beside it —moving the money, filing the taxes, managing W-2s, resolving notices and interacting with tax agencies. Bringing those capabilities together creates a compelling end-to-end payroll tax solution and another meaningful avenue for Asure to gain market share.”

Three New Paths to Payroll Tax Management Growth

The strategic alliance establishes multiple commercial channels through which the companies expect to expand their respective payroll tax businesses. As enterprises modernize payroll and ERP infrastructure, the companies intend to offer customers a migration path that combines modern tax calculation technology with outsourced payroll tax filing and compliance.

First, Asure will be able to offer Vertex payroll tax calculation technology together with Asure Payroll Tax Management to Asure customers and prospects. The side-by-side offering expands Asure’s ability to compete for organizations seeking a one-stop payroll tax calculation and downstream tax filing, remittance and compliance solution.

Second, the companies expect to pursue opportunities within the payroll and HCM provider ecosystem. The partnership can pair Vertex technology with Asure’s existing relationships with payroll service providers and other application service providers, creating another potential source of recurring Payroll Tax Management customers.

Together, these channels make it easier for Asure to be considered beyond customers purchasing tax filing services independently and into organizations seeking a more comprehensive payroll tax technology and compliance solution.

Moving Upstream in the Payroll Tax Technology Stack

Payroll tax management requires two complementary capabilities: accurately determining what an employer owes and then successfully depositing, filing and reconciling those obligations with government agencies.

Vertex brings nearly five decades of tax experience and decades of tax technology expertise, along with many years of cloud-based payroll tax calculation capabilities covering federal, state and local requirements in the United States and Canada.

Asure brings the operational compliance infrastructure that follows calculation, including tax filing, remittance, W-2 preparation, notice and amendment management and government agency interaction. Asure currently provides payroll tax and compliance services supporting more than 100,000 businesses and more than two million employees nationwide, plus a growing number of large enterprises representing multiple millions of employees

The partnership therefore expands Asure’s position from payroll tax compliance provider toward a broader end-to-end payroll tax solution.

“Payroll tax is one of the most complex compliance obligations an employer carries, and the requirements change constantly across thousands of jurisdictions,” said Chirag Patel, Chief Strategy Officer at Vertex. “Vertex has spent decades helping organizations calculate payroll taxes accurately. Working with Asure connects that calculation expertise with filing and remittance, helping create a more seamless path from determining what’s owed to meeting those obligations.”

“The financial significance is not simply another referral agreement,” Goepel said. “It is about distribution. Every additional payroll platform, enterprise relationship and technology ecosystem that can connect to Asure PTM expands access. Our objective is straightforward: make Asure the infrastructure layer behind an increasing share of payroll tax filings and tax money movement in the United States.”

About Asure Software

Asure Software (Nasdaq: ASUR) provides cloud-based Human Capital Management solutions delivered as Payroll, Payroll Tax Management, HR compliance and related services. Asure’s Payroll Tax Management infrastructure supports tax filing, remittance, W-2 processing, agency notice management and other payroll tax compliance requirements for businesses and payroll providers across the United States.

For more information, visit AsureSoftware.com.

Forward-Looking Statements

Statements in this press release that are not historical facts, including statements regarding the expected benefits of the strategic partnership, potential customer adoption, market opportunities, addressable market expansion, revenue opportunities, market-share gains, product integration, customer migrations and future financial performance, are forward-looking statements within the meaning of applicable federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers should refer to Asure Software’s filings with the Securities and Exchange Commission for a discussion of risks and uncertainties affecting the Company’s business. Asure undertakes no obligation to update forward-looking statements except as required by law.

Investor Relations Contact

Patrick McKillop
Vice President, Investor Relations
Asure Software
617-335-5058
patrick.mckillop@asuresoftware.com

Discussion to Highlight Proprietary Technologies and Partnerships with Square Roots and Caney Fork Farms as Foundations for Growth Beyond Core CEA

Jim Kras will discuss Diversification Beyond Core CEA at CEAg World Conference & Expo

BELVIDERE, NJ, Nov. 02, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that Chief Executive Officer Jim Kras will participate in the 2026 CEAg World Conference & Expo, taking place November 10–11, 2026, in Charlotte-Concord, North Carolina.

Mr. Kras will participate in a session titled “Diversification Beyond Core CEA” on Tuesday, November 10, 2026. He is expected to discuss how Edible Garden is building on its growing expertise, proprietary technologies and retail relationships to expand into value-added foods, clean-label nutrition and ready-to-drink beverages. The discussion will also address how strategic partnerships can support product innovation, broaden sourcing capabilities and create opportunities for growth beyond traditional greenhouse operations.

“Innovation has always been central to Edible Garden, from our patented GreenThumb software and Self-Watering displays to our Zero-Waste Inspired® approach to growing and delivering fresh produce,” said Jim Kras, Chief Executive Officer of Edible Garden. “Our Farm-to-Formula® strategy builds on that foundation by connecting our agricultural expertise with opportunities in clean-label foods, nutrition and ready-to-drink beverages. Diversification means applying what we do well to new categories where we believe we can create value for retailers and consumers.”

Edible Garden’s recent partnerships with Square Roots and Caney Fork Farms are intended to support this diversification strategy. The Square Roots relationship adds a collaborative avenue for exploring crop innovation and new product concepts, while the Caney Fork Farms partnership brings regenerative agriculture into the Company’s broader supply strategy. Together, these relationships are intended to complement Edible Garden’s CEA capabilities and support a broader range of ingredients, products and market opportunities.

“Our partnerships with Square Roots and Caney Fork Farms demonstrate how we are bringing complementary expertise into our business,” Mr. Kras continued. “We see opportunities to connect innovation in controlled environment agriculture with regenerative farming and product development, helping us broaden our offering while pursuing a more flexible operating model. As we develop our Prairie Hills ready-to-drink platform, these relationships can help inform future product innovation and support our goal of building a more diversified revenue base across fresh produce and shelf-stable nutrition.”

The CEAg World Conference & Expo brings together commercial growers, industry executives, technology providers, and other stakeholders to discuss the challenges and opportunities shaping the future of controlled environment agriculture. The 2026 conference will focus on practical strategies for improving profitability, managing costs, strengthening customer relationships, and building more resilient growing operations.

Additional information about the conference is available at https://www.ceagworld.com/events/.

ABOUT EDIBLE GARDEN^®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired^® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way^® and Vitamin Whey^®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “expand,” “extend,” “transform,” “strategy,” “advance,” “create,” “initiative,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements include, without limitation, statements regarding the Company’s ability to expand and strengthen its operations, the development of the Company’s ready-to-drink manufacturing facility in Webster City, Iowa, the Company’s Farm-to-Formula® strategy, the anticipated benefits of its partnerships with Square Roots and Caney Fork Farms, and its plans to diversify products, markets and revenue streams. Forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including those described in the “Risk Factors” section and other sections of the Company’s reports filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
EDBL@crescendo-ir.com

Attachment

• Jim Kras will discuss Diversification Beyond Core CEA at CEAg World Conference & Expo

Siemens and AES veteran executives Axel Meier and Ricardo Roizen appointed Interim CEO and Interim CFO; global operations and transformation executive Marco Boos named Senior Vice President & Chief Customer Success Officer

Board of Directors establishes Manufacturing and Operations Oversight Committee to provide focused oversight of transformation

ARLINGTON, Va., Nov. 02, 2026 (GLOBE NEWSWIRE) — Fluence Energy, Inc. (“Fluence” or the “Company”) (NASDAQ: FLNC) today announced a series of executive leadership changes that mark an important step in the Company’s ongoing operational transformation. These leadership changes add proven experience in financial management, operational transformation, manufacturing, and customer delivery as Fluence works to strengthen production systems and processes, improve execution, and reinforce financial discipline.

“The Board is taking decisive action to strengthen leadership, sharpen accountability, and support Fluence’s long-term success,” said Herman Bulls, Chairman of the Fluence Board of Directors. “We believe Fluence has tremendous potential and a significant market opportunity ahead. We are confident that these leadership changes, together with the additional steps the Board is taking to advance the Company’s transformation, will position Fluence for the future and create lasting value for our employees, customers, and shareholders.”

Fluence enters this next phase with important competitive strengths, including Smartstack™’s differentiated technology, high energy density, and modular architecture, and a record backlog of $6.4 billion, as reported in the Company’s fiscal third-quarter 2026 results. Building on this foundation, the Board and management are focused on improving financial and operational execution, delivering on commitments to customers, strengthening cash generation, and prioritizing sustainable, profitable growth through disciplined pricing and a streamlined cost structure.

Axel Meier Appointed Interim CEO; Ricardo Roizen Appointed Interim CFO

Axel Meier has been appointed Interim Chief Executive Officer, effective immediately, succeeding Julian Nebreda, who has stepped down as President and Chief Executive Officer. Mr. Meier has served on Fluence’s Board of Directors since 2020 and recently retired as Chief Financial Officer of Siemens Smart Infrastructure. He brings more than three decades of experience at Siemens, including senior leadership roles across its infrastructure, industry, and technology businesses. As CFO of Siemens Smart Infrastructure, Mr. Meier helped shape the business into a reliable performer, delivering consistent above-market growth, year-over-year profit margin expansion for 23 consecutive quarters, and disciplined cash conversion.

In addition, Ricardo Roizen has been appointed Interim Chief Financial Officer, effective immediately, succeeding Ahmed Pasha, who has stepped down as Senior Vice President & Chief Financial Officer. Mr. Roizen previously served as Chief Financial Officer of AES Andes and brings more than a decade of financial leadership experience with AES, spanning corporate finance, financial planning, business analysis, and treasury functions.

“Axel and Ricardo understand Fluence, its industry, and the opportunity ahead, and they will work closely with the broader leadership team to bring urgency, rigor, and accountability to the Company’s transformation,” said Mr. Bulls. “On behalf of the Board, I want to thank Julian for his leadership of Fluence. We also wish Ahmed the best and appreciate his service as CFO.”

“I am honored to step into this role at an important time for Fluence,” said Mr. Meier. “The Company has strong technology, talented people, and a compelling position in a growing market. Our mission and priorities are clear: delivering on our commitments to our customers, strengthening execution, and advancing the transformation work already underway across the business. I look forward to working with the entire Fluence team to drive progress in each of these areas.”

Fluence has begun searches for permanent leaders for the Chief Executive Officer and Chief Financial Officer roles.

Bernerd Da Santos to Lead Operational Transformation; Marco Boos Appointed Senior Vice President & Chief Customer Success Officer

Bernerd Da Santos will continue to serve as Chief Operating Officer and will lead the Company’s operational transformation, working closely with Mr. Meier and the executive leadership team. His responsibilities will include execution, supply chain, product development, commercial performance, and customer delivery, with a focus on measurable improvements in operational and financial performance.

Fluence also announced that Marco Boos has been appointed Senior Vice President & Chief Customer Success Officer, effective November 15. Mr. Boos brings more than 25 years of global operations and transformation experience, with senior leadership roles spanning supply chain, manufacturing, and operational performance at Proenergy, Weatherford, ABB, and Siemens. Mr. Boos succeeds John Zahurancik, who has stepped down from the position.

“Marco brings deep experience in manufacturing, operational transformation, and performance improvement, as well as a strong record of delivering for customers. His appointment adds important capabilities to the leadership team,” said Mr. Bulls. “We are grateful to John for his contributions to Fluence.”

Mr. Meier, Mr. Roizen, and Mr. Boos will join Mr. Da Santos; Vincent Mathis, Senior Vice President & Chief Legal and Compliance Officer and Secretary; Jeff Monday, Senior Vice President & Chief Growth Officer; and Roman Loosen, Senior Vice President & Chief Supply Chain and Manufacturing Officer, as part of Fluence’s executive leadership team.

Board Establishes Manufacturing and Operations Oversight Committee

The Fluence Board of Directors has established a new Manufacturing and Operations Oversight Committee to provide focused oversight of the Company’s efforts to strengthen manufacturing performance, operational execution, and customer delivery. The committee reflects the Board’s commitment to disciplined execution and sustained operational improvement.

The Board committee will be chaired by Stephan May and will include Stephen Coughlin and Elizabeth Fessenden. Mr. May and Ms. Fessenden bring significant expertise in manufacturing and manufacturing processes, while Mr. Coughlin brings extensive finance leadership experience in the energy industry.

Fluence’s operational transformation is supported by major shareholders Siemens AG and The AES Corporation, whose global experience and capabilities provide important support as the Company moves forward.

Fiscal Year 2026 Earnings Call and 2027 Guidance Timing

The Company will report financial results for fiscal year 2026 after market close on Monday, November 23, followed by a year-end earnings call before market open on Tuesday, November 24 at 8:30 a.m. ET. To participate, analysts are required to register by clicking Fluence Energy Q4 2026 Earnings Call Registration Link. Once registered, analysts will be issued a unique PIN number and dial-in number. Analysts are encouraged to register at least 15 minutes before the scheduled start time.

Other participants are encouraged to join the teleconference in a listen-only mode at: Listen-Only Mode – Webcast Link, or on https://fluenceenergy.com/ by selecting Investors, News & Events, and Events & Presentations. Supplemental materials that may be referenced during the teleconference will be available at: www.fluenceenergy.com, by selecting Investors, News & Events, and Events & Presentations.

A replay of the conference call will be available after 1:00 p.m. ET on November 24. The replay will be available on the Company’s website at https://fluenceenergy.com/ by selecting Investors, News & Events, and Events & Presentations.

Financial guidance for fiscal year 2027 is expected to be provided at a later date.

About Fluence

Fluence Energy, Inc. (Nasdaq: FLNC) is a global market leader delivering intelligent energy storage and optimization software for renewables and storage. The Company’s solutions and operational services are helping to create a more resilient grid, from powering the next generation of AI-driven data centers to unlocking the full potential of renewable portfolios. With gigawatts of projects successfully contracted, deployed, and under management across nearly 50 markets, the Company is transforming the way we power our world for a more sustainable future.

For more information, visit our website, or follow us on LinkedIn or X. To stay up to date on the latest industry insights, sign up for Fluence’s Full Potential Blog.  

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the Company’s operational transformation, potential benefits of the executive leadership changes, future market opportunity, future operational or financial execution and performance, future cash flows, ability to create lasting value for employees, customers, and shareholders, competitive strengths, ability to achieve and maintain sustainable, profitable growth, ability to deliver on customer commitments, expectations related to backlog, and any other statements regarding the Company’s business, growth, or future performance and the beliefs, assumptions, prospects, plans, and objectives of management and timing associated therewith. Such statements can be identified by the fact that they do not relate strictly to historical or current facts. When used in this press release, words such as “may,” “possible,” “will,” “should,” “seeks,” “expects,” “plans,” “anticipates,” “grows,” “could,” “intends,” “targets,” “projects,” “contemplates,” “commits,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions and variations thereof and similar words and expressions are intended to identify such forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments, as well as a number of assumptions concerning future events, and their potential effects on our business. These forward-looking statements are not guarantees of performance, and there can be no assurance that future developments affecting our business will be those that we have anticipated, and actual results may prove to be materially different from the results expressed or implied by the forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties, and other important factors that could cause actual results to differ materially from those in the forward-looking statements, including, but not limited to, the elimination or expiration of government incentives or regulations regarding renewable energy; changes in the global trade environment; fluctuations in order intake and results of operations across fiscal periods; a significant reduction in order volume or loss of significant customers or their inability to perform under contracts; competition for offerings and the ability to attract new customers and retain existing ones; maintaining and enhancing reputation and brand recognition; our ability to manage recent and future growth and the expansion of our business and operations; our ability to attract and retain highly qualified personnel; our growth depending on the success of relationships with third parties; delays, disruptions, and quality control problems in manufacturing operations; risks associated with engineering and construction, utility interconnection, commissioning and installation of energy storage products, cost overruns, and delays; supplier concentration and limited supplier capacity; operating as a global company with a global supply chain; changes in the cost and availability of raw materials and underlying components; lengthy sales and installation cycle for energy storage solutions; quality and quantity of components provided by suppliers; defects, errors, vulnerabilities, and/or bugs in products and technology; events and incidents relating to storage, delivery, installation, operation, maintenance, and shutdowns of products; current and planned foreign operations; failure by contract manufacturers, vendors, and suppliers to use ethical business practices and comply with applicable laws and regulations; actual or threatened health epidemics, pandemics, or similar public health threats; severe weather events; acquisitions made or that may be pursued; our ability to obtain financial assurances for projects; relatively limited operating and revenue history as an independent entity and the nascent clean energy industry; anticipated increases in expenses in the future and our ability to maintain prolonged profitability; the risk that amounts included in the pipeline and contracted backlog may not result in actual revenue or translate into profits; restrictions set forth in current and future credit and debt agreements; our uncertain ability to raise additional capital to execute on business opportunities; fluctuations in currency exchange rates; whether renewable energy technologies are suitable for widespread adoption or if sufficient demand for offerings does not develop or takes longer to develop than anticipated; our estimates on the size of the total addressable market; macroeconomic uncertainty and market conditions; interest rates or a reduction in the availability of tax equity or project debt capital in the global financial markets and corresponding effects on customers’ ability to finance energy storage systems and demand for energy storage solutions; the cost of electricity available from alternative sources; a decline or delay in public acceptance of renewable energy, or increase in the cost of customer projects; increased attention to environmental, social and governance matters; our ability to obtain, maintain, and enforce proper protection for intellectual property, including technology; the threat of lawsuits by third parties alleging intellectual property violations; our having adequate protection for trademarks and trade names; our ability to enforce intellectual property rights; our patent portfolio; our ability to effectively protect data integrity of technology infrastructure, data, and other business systems; the use of open-source software; our failure to comply with third-party license or technology agreements; our inability to license rights to use technologies on reasonable terms; compromises, interruptions, or shutdowns of systems; use of artificial intelligence (“AI”) technologies; potential changes in tax laws or regulations; barriers arising from current electric utility industry policies and regulations and any subsequent changes; environmental, health, and safety laws and potential obligations, liabilities, and costs thereunder; actual or perceived failure to comply with data privacy and data security laws, regulations, industry standards, and other requirements relating to the privacy, security, and processing of personal information; potential future legal proceedings, regulatory disputes, and governmental inquiries; ownership of our Class A common stock; short-seller activists; being a “controlled company” within the meaning of the rules of the Nasdaq Stock Market; conflicts of interest by officers and directors due to positions with our continuing equity owners; relationship with our founders and continuing equity owners; terms of our amended and restated certificate of incorporation and amended and restated bylaws; our dependence on distributions from Fluence Energy, LLC to pay taxes and expenses and Fluence Energy, LLC’s ability to make such distributions may be limited or restricted in certain scenarios; risks arising out of the Tax Receivable Agreement; unanticipated changes in effective tax rates or adverse outcomes resulting from examination of tax returns; risks related to the 2030 Convertible Senior Notes; improper and ineffective internal control over reporting to comply with the Sarbanes-Oxley Act; changes in accounting principles or their applicability; and estimates or judgments relating to critical accounting policies; and other important factors described under Part I, Item 1A. “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2025, filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 25, 2025, as updated from time to time in our filings with the SEC. New risks and uncertainties emerge from time to time and it is not possible for us to predict all such risk factors, nor can we assess the effect of all such risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of the assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You are cautioned not to place undue reliance on any forward-looking statements made in this press release. Each forward-looking statement speaks only as of the date of the particular statement, and we undertake no obligation to publicly update or revise any forward-looking statements to reflect events or circumstances that occur, or which we become aware of, after the date hereof, except as otherwise may be required by law.

Media Contact  
Shayla Ebsen, Director of Communications  
Email: media.corporate@fluenceenergy.com

Analyst Contact   
Chris Shelton, Vice President of Finance, GID, and IR 
Email: investorrelations@fluenceenergy.com 

• Phase 1 clinical trial to evaluate local intravesical administration of UGN-501
• UGN-501 is a differentiated investigational next-generation oncolytic virus designed to combine direct tumor cell destruction with anti-tumor immune activation

PRINCETON, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) — UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the first patient was dosed with UGN-501, a next-generation investigational oncolytic virus. The Phase 1 trial will evaluate the safety, tolerability, and feasibility of intravesical administration of UGN-501.

“The first patient dosed with UGN-501 marks an important step in advancing this investigational therapy from nonclinical research into clinical evaluation,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “We can now begin to understand its safety and tolerability in patients with NMIBC and generate insights to guide its continued development. This progress brings us closer to our goal of expanding treatment options for patients with bladder cancer.”

The Phase 1, open-label, dose-escalation trial is designed to evaluate the safety, tolerability and pharmacokinetics of intravesically administered UGN-501 and determine the recommended Phase 2 dose in adults with recurrent non-muscle invasive bladder cancer (NMIBC), including high-grade Ta/T1 disease and/or carcinoma in situ (CIS), or low-grade Ta/T1 disease. Before treatment, all visible papillary tumors must be resected and obvious areas of CIS fulgurated. Participants will receive an aqueous formulation of UGN-501 through six once-weekly intravesical instillations during a 12-week induction period. Participants with no evidence of disease at week 12 may proceed to maintenance treatment consisting of three once-weekly instillations administered quarterly from month three through month 12, or until disease recurrence, disease progression or death, whichever occurs first, with a safety follow-up visit at month 15. For more information about the Phase 1 trial, go to ClinicalTrials.gov at NCT07725796.

In parallel with the Phase 1 trial, UroGen is conducting nonclinical studies exploring the formulation of UGN-501 in its proprietary RTGel^® technology. The formulation being evaluated in the current Phase 1 trial is aqueous and does not contain RTGel.

NMIBC continues to present significant clinical challenges, particularly among patients whose disease recurs following standard treatment. Despite available therapies, recurrence rates remain substantial, underscoring the need for novel bladder-sparing therapeutic approaches. UroGen believes UGN-501’s differentiated mechanism of action and local administration strategy may offer a promising new approach for addressing this unmet need.

About UGN-501

UGN-501 is an investigational, next-generation oncolytic virus being investigated for the treatment of non-muscle invasive bladder cancer (NMIBC). UGN-501 is designed to selectively replicate within tumor cells, resulting in direct tumor cell destruction and an anti-tumor immune response. The program is supported by nonclinical data demonstrating cytotoxic activity across a broad panel of bladder cancer cell lines representing multiple stages and grades of disease. While UGN-501 is initially being developed for bladder cancer, the Company believes UGN-501’s underlying properties may have broader applicability across additional solid tumor indications and intends to evaluate future development opportunities based on emerging clinical and translational data.

About UroGen Pharma Ltd.

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Our first product to treat low-grade upper tract urothelial cancer and our second product to treat adult patients with recurrent LG-IR-NMIBC, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

Visit www.UroGen.com to learn more or follow us on X (formerly Twitter), @UroGenPharma.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding: the progress and plans for the Phase 1 clinical trial of UGN-501 in NMIBC; UroGen’s nonclinical studies exploring the formulation of UGN-501 in its proprietary RTGel technology; the design and potential benefits of UGN-501, including to selectively replicate within tumor cells, resulting in direct tumor cell destruction and an anti-tumor immune response, and its differentiated mechanism of action and local administration strategy potentially offering a promising new approach for addressing un unmet need; UGN-501’s potential for broader applicability across additional solid tumor indications; UroGen’s plans to evaluate future development opportunities for NMIBC based on emerging clinical and translational data; the belief that UGN-501 has several attributes that differentiate it from other oncolytic viruses; the potential of UroGen’s proprietary RTGel technology to improve therapeutic profiles of existing drugs or UGN-501 and UroGen’s sustained release technology making local delivery potentially more effective as compared to other treatment options. Words such as “believe,” “can,” “expect,” “intend,” “may,” “plan,” “potential,” “will,” or other words that convey uncertainty of future events or outcomes are used to identify these forward-looking statements. These statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: nonclinical results may not be indicative of results that may be observed in clinical trials; the labeling for any approved product; competition in UroGen’s industry; the scope, progress and expansion of developing and commercializing UroGen’s product candidates; the size and growth of the market(s) therefor and the rate and degree of market acceptance thereof vis-à-vis alternative therapies; UroGen’s ability to attract or retain key management, members of the board of directors and other personnel; UroGen’s RTGel technology may not perform as expected, including when formulated with UGN-501; UroGen’s financial condition and need for additional capital; and UroGen may not successfully develop and receive regulatory approval of a product candidate, including ones that incorporate RTGel technology. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section of UroGen’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on August 5, 2026 (which is available at www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and UroGen’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to UroGen as of the date of this release.

INVESTOR:
Vincent Perrone
Senior Director, Investor Relations
vincent.perrone@urogen.com
609-460-3588 ext. 1093

MEDIA:
Cindy Romano
Director, Corporate Communications
cindy.romano@urogen.com
609-460-3566 ext. 1083

Milestone advances Callan JMB’s domestic pharmaceutical manufacturing strategy and is expected to create a new high-margin healthcare manufacturing revenue stream at their Texas facility.

SPRING BRANCH, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) — Callan JMB, Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a diversified healthcare logistics, preparedness, and critical infrastructure company, today announced that it has received a complete QuickStrip^™ oral thin-film production line from Rapid Dose Therapeutics Corp. (“RDT”) for installation at the Company’s facility in Texas.

The arrival of the manufacturing system completes another significant step in Callan JMB’s strategy to expand its pharmaceutical services platform through domestic manufacturing, packaging, fulfillment, distribution, and increase our healthcare preparedness capabilities. This equipment delivery launches our entry into the market for the production of innovative oral thin-film delivery products in the United States.

The collaboration comes amid growing interest in oral thin-film drug delivery technologies as demand grows for alternative pharmaceutical dosage formats. This arrangement combines RDT’s proprietary QuickStrip^™ oral thin-film technology with Callan JMB’s infrastructure, regulatory expertise, healthcare logistics network, and pharmaceutical distribution capabilities. Once installed the production line will provide the foundation for U.S.-based manufacturing of fast-dissolving oral thin-film products for pharmaceutical, nutraceutical, and government healthcare applications.

Callan JMB currently believes that the oral thin-film manufacturing platform will generate up to $15 million in revenue during the first 18 months of operation, post the successful qualification of the equipment.

“This shipment is an important milestone in our vision to fast track the building of a comprehensive U.S.-based pharmaceutical manufacturing and healthcare logistics platform,” said Wayne Williams, Chief Executive Officer of Callan JMB. “We continue to implement capabilities that will help us reach our goal of strengthen healthcare supply chain resiliency, support domestic manufacturing, and create long-term value for our customers and shareholders. We believe oral thin-film delivery technology represents one of the most promising segments of pharmaceutical innovation today. Today’s positive announcement demonstrates our commitment to a rapid roll out of these advancements.”

Williams continued, “This new opportunity aligns directly with our strategy of leveraging our existing infrastructure and healthcare logistics capabilities to create scalable, recurring revenue streams while supporting domestic pharmaceutical manufacturing. Neither the completion of this project nor the recently announced IV Bag manufacturing facility require us to raise any additional capital.“

About QuickStrip^™

QuickStrip^™ is Rapid Dose Therapeutics’ proprietary oral thin-film drug delivery platform. The technology utilizes rapidly dissolving oral strips designed to deliver active ingredients efficiently and conveniently without the need for water or traditional dosage forms. The platform has potential applications across pharmaceuticals, nutraceuticals, wellness products, emergency preparedness programs, and other healthcare markets.

About Callan JMB

Callan JMB, Inc. (NASDAQ: CJMB) is a diversified healthcare logistics, preparedness, and manufacturing, and critical infrastructure company serving healthcare organizations, government agencies, and commercial customers. The Company provides fulfillment, warehousing, cold-chain logistics, monitoring, regulatory compliance, specialty packaging, pharmaceutical support services, and emergency preparedness solutions designed to strengthen supply chains and protect critical products.

Through strategic partnerships, acquisitions, and organic growth initiatives, Calen JMB is building a platform spanning healthcare and pharmaceutical logistics, domestic pharmaceutical manufacturing, critical electrical infrastructure, specialty industrial manufacturing, preparedness services, and energy development.

For more information, visit www.callanjmb.com.

Investor Contact

Valter Pinto
Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
(212) 896-1254

Media Contact

Arian Hopkins
ahopkins@callanjmb.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the anticipated installation, qualification, operation, commercialization, revenue generation, and future utilization of the QuickStrip^™ production line; the expected benefits of the collaboration with Rapid Dose Therapeutics; projected revenues; and future business opportunities. Forward-looking statements are based on management’s current expectations and assumptions and are subject to numerous risks and uncertainties, including customer adoption, regulatory approvals, product qualification, market conditions, and execution risks. Actual results may differ materially from those described in forward-looking statements. Readers are cautioned not to place undue reliance on such statements. Callan JMB undertakes no obligation to update any forward-looking statements except as required by applicable law.

Oral tablet form expected to allow Company to optimize patient plasma exposure levels with convenient daily dosing of drug

Sustained plasma levels of elraglusib expected to have multiple effects on immune cell dynamics with potential to enhance anti-tumor immune response

Patent allowance advances protection for Elraglusib Oral Tablet ahead of planned Phase 1/2 clinical trial in Q1 2027

CHICAGO and FORT WORTH, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) — Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 19/669,218, titled “Oral Dosage Forms of Elraglusib.” The allowed claims cover the composition of oral tablet forms of elraglusib, an inhibitor of GSK-3β, the Company’s lead clinical investigational candidate, including the optimized Elraglusib Oral Tablet developed for upcoming use in clinical trials.

Elraglusib Oral Tablet is being developed to enable convenient daily dosing with the potential to provide sustained GSK-3β inhibition, leading to enhanced antitumor activity. Pre-clinical and clinical exposure-effect analysis has identified threshold plasma levels of elraglusib associated with clinical benefit, inhibition of tumor growth and reduction in tumor size. Sustained exposure of elraglusib has been observed to elicit direct effects on tumor cells as well as a unique array of complementary effects on anti-tumor immune response that lead to increased CD8+ and NK cell recruitment, attenuation of immune suppressive features and altering the tumor immune microenvironment to prime the tumor for sustained anti-tumor immune response. To date, elraglusib has been administered intravenously (Elraglusib Injection) using weekly or twice weekly intermittent dosing in several clinical studies in refractory and resistant adult and pediatric cancers.

Elraglusib Oral Tablet is a key part of Actuate’s clinical development strategy, with potential utility as a monotherapy and in combination treatment and maintenance therapy approaches. Actuate plans to initiate a Phase 1/2 clinical trial of Elraglusib Oral Tablet in the first quarter of 2027 to evaluate its safety, tolerability, pharmacokinetics and screen for initial evidence of antitumor activity in patients with advanced cancer.

“The development of an optimized oral tablet dosage form marks an important advance in realizing elraglusib’s therapeutic potential,” said Daniel Schmitt, President and Chief Executive Officer of Actuate Therapeutics. “Daily oral administration is expected to enable sustained plasma drug exposure and inhibition of GSK-3 in a tumor, potentially promoting sustained changes in immune cell dynamics that favor antitumor immune responses. This approach could also provide greater dosing flexibility and patient convenience and expand opportunities to investigate elraglusib as both a monotherapy and in combination with other cancer treatments.”

“The allowance of this patent application represents an important milestone in strengthening our intellectual property portfolio around oral formulations of elraglusib including protection for the oral tablet dosage form,” said Andrew Mazar, PhD, Chief Operating Officer at Actuate Therapeutics. “With our imminent Phase 1/2 clinical trial, we anticipate being able to more fully explore the clinical potential of elraglusib in the next stage of development as we bring a new oral treatment option with a unique immunomodulatory mechanism of action to cancer patients in need.”

The patent, upon completion of customary USPTO procedures, is expected to further strengthen Actuate’s intellectual property portfolio, support continued stage appropriate development, leading to the future potential commercialization of oral elraglusib.

About Actuate Therapeutics, Inc.

Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in activation of anti-tumor immunity through the regulation of multiple immune checkpoints and immune cell function in addition to targeting those promoting tumor growth and resistance to conventional chemotherapy.

For additional information, please visit the Company’s website at www.actuatetherapeutics.com or follow us on LinkedIn, X, and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including statements regarding the expected issuance of a patent from U.S. Patent Application No. 19/669,218, the scope of protection it may provide, the anticipated timing and design of a Phase 1/2 clinical trial of the Elraglusib Oral Tablet, and the potential benefits of oral elraglusib, including its potential to enhance antitumor activity, improve patient convenience and expand therapeutic applications. Forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially, including (i) the risk that we may not be able to commence or complete our expected Phase 1/2 trial of Elraglusib Oral Tablet or, if we can, that the Phase 1/2 trial may not produce positive results, (ii) success in early phases of clinicals trials do not ensure later clinical trials will be successful; (iii) the risk that the Company may not be able to obtain additional working capital with which to complete the Phase 1/2 clinical trial, or advance to the initiation of registration-enabling studies, for Elraglusib Oral Tablet as and when needed and (iv) those other risks disclosed under the caption “Risk Factors” in Actuate’s Annual Report of Form 10-K filed with the Securities and Exchange Commission on March 26, 2026 and in Actuate’s subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Actuate does not undertake and specifically disclaims any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.

Investor Contact

Mike Moyer
Managing Director
LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com

Media Contact

Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
ignacio.guerrero-ros@russopartnersllc.com
(858) 717-2310

Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug Administration

Reported positive Phase 1 imaging data for RAD301, supporting advancement toward Phase 2 development in pancreatic ductal adenocarcinoma

Advanced to fourth dosing cohort in ongoing Phase 1 ‘HEAT’ study of RAD202 in HER2+ solid tumors

SYDNEY, Nov. 02, 2026 (GLOBE NEWSWIRE) — Radiopharm Theranostics (ASX: RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced financial results for the quarter ended September 30, 2026, and provided a corporate update.

“We continue to execute on multiple value-driving catalysts across our portfolio, with the successful End-of-Phase 2 meeting for RAD101 representing a particularly important milestone as we prepare to enter a pivotal Phase 3 study,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “The progress achieved this quarter reflects both the growing maturity of our pipeline and the differentiated potential of our radiopharmaceutical platform. From advancing RAD202, RAD204 and RV-01 in the clinic to reporting positive Phase 1 imaging data for RAD301, we are steadily building a robust body of clinical evidence across several high-value oncology targets. With multiple upcoming clinical, regulatory and scientific milestones anticipated over the coming months, we believe Radiopharm is well positioned to continue generating momentum as we work to develop the next generation of precision cancer therapies for patients with significant unmet needs.”

Program and Business Updates

18F-RAD101 – Small molecule targeting fatty acid synthase radiolabeled with Fluorine-18

RAD101 is currently being prepared for a pivotal, multi-center, global Phase 3 imaging trial following a productive End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) in individuals with confirmed recurrent brain metastases from solid tumors of different origins. RAD101 has received FDA Fast Track Designation to distinguish between recurrent disease and treatment effect of brain metastases originating from solid tumors of different origin including leptomeningeal disease. The company also recently announced a partnership with Siemens Healthineers, who will manufacture and distribute doses of 18F-labeled RAD101 to support Radiopharm’s upcoming Phase 3 registrational trial in the U.S.

• In October 2026, the Company announced the successful completion of an EOP2 meeting with the FDA for RAD101 for the detection of brain metastases. Previously reported Phase 2b clinical data showed that RAD101 demonstrated 93% concordance with MRI across all evaluable lesions, meeting the Phase 2 trial’s primary endpoint.

• RAD101 was selected for a late-breaking oral presentation of interim Phase 2b imaging data for its trial in participants with suspected recurrent brain metastases from solid tumors at the 31^st Annual Meeting of the Society of Neuro-Oncology (SNO26) taking place from November 12-15, 2026, in Philadelphia, Pennsylvania. The data from these findings are supportive for the initiation of the Phase 3 imaging trial.

177Lu-RAD204 – Nanobody targeting PD-L1 radiolabeled with Lutetium 177

RAD204 is being evaluated in a Phase 1 study in PD-L1-driven cancers, including Non-Small Cell Lung Cancer (NSCLC), Small-Cell Lung Cancer (SCLC), Triple-negative Breast Cancer (TNBC), Cutaneous Melanoma, head and neck squamous cell carcinoma (HNSCC) and Endometrial Cancer.

• The Company continues to make progress in dosing patients in the 90mCi third cohort of the Phase 1 study. Data from each of the cohorts of the Phase 1 study will be used to inform the recommended dose for the planned Phase 2 trial.

177Lu-RAD202 – Nanobody targeting HER2 radiolabeled with Lutetium 177

The Company continues to evaluate RAD202 in the Phase 1 ‘HEAT’ clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors. HER2 is overexpressed in breast cancer and several other solid tumors and represents a validated target in oncology. RAD202 has demonstrated clinical proof-of-concept with positive safety and biodistribution.

• In August 2026, the Company received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance RAD202 to the next dose level of 180mCi in the fourth cohort of the Phase 1 ‘HEAT’ clinical trial in patients with HER2-positive advanced solid tumors.

Lu177-RV 01 – monoclonal antibody targeting 4Ig isoform of B7H3 radiolabeled with Lutetium 177

RV-01 (Betabart) is a monoclonal antibody targeting the 4Ig isoform of B7H3, an immune checkpoint protein that is highly expressed in tumors and not in healthy tissue. In multiple preclinical studies, RV-01 has shown tumor shrinkage and prolonged survival. This is the first radiopharmaceutical therapeutic developed by Radiopharm Ventures, a joint venture between Radiopharm Theranostics and the MD Anderson Cancer Center.

• In August 2026, the Company dosed the first patient in the second cohort of its First-In-Human (FIH) Phase 1/2 clinical trial of RV-01 in patients with B7-H3 expressing tumors. The dosing of the first patient came following a positive recommendation from the Safety and Monitoring Committee (SMC) to advance to the 70mCi dose.
• The Phase 1/2a clinical trial of RV-01 is a dose escalation and expansion trial designed to evaluate the safety, biodistribution, radiation dosimetry and preliminary anti-tumor activity of RV-01 in B7-H3 expressing tumors. The trial will determine the recommended dose of RV-01 to move forward in future studies. The Phase 1/2a study is currently being conducted at clinical centers across the U.S.

Tb161-RAD 402 – Monoclonal antibody targeting KLK3 radiolabeled with Terbium 161

RAD402 is a monoclonal antibody targeting Kallikrein Related Peptidase 3 (KLK3) radiolabeled with the radionuclide 161Tb for the treatment of prostate cancer. In preclinical mouse models, RAD 402 showed strong tumor targeting, limited bone and marrow uptake, and a hepatic excretion profile consistent with expectations for a monoclonal antibody.

• The Company continues to progress its First-In-Human (FIH) Phase 1 clinical trial of RAD402, designed to evaluate the safety, tolerability, whole-body distribution, and preliminary clinical activity of RAD402 in patients with advanced prostate cancer. The dose escalation Phase 1 study is designed to determine the Maximum Tolerated Dose and recommended Phase 2 dose for expansion.

Ga68-RAD301 – Peptide targeting αvB-integrin radiolabeled with Gallium 68

RAD301 is being evaluated in a Phase 1 imaging trial in patients with Pancreatic Ductal Adenocarcinoma (PDAC). The αvB-integrin is a cellular marker for tumor invasion and metastatic growth, which correlates with decreased survival in several carcinomas, particularly pancreatic. RAD301 has previously received Orphan Drug Designation (ODD) from the FDA and data from the Phase 1 trial is supportive of continuing its development.

• In September 2026, the Company announced positive data from the Phase 1 trial of RAD301 in patients with pancreatic ductal adenocarcinoma. RAD301 demonstrated a favorable safety profile in all evaluable participants as well as favorable biodistribution and significant tumor uptake in pancreatic cancer metastases, which supports the potential of αvβ6-integrin as a target for future therapeutic development and potentially as a theranostic pair.

Radiopharm Ventures

Subsequent to 30 September, Radiopharm increased its ownership In Radiopharm Ventures from 87.5% to 93.75% as the result of continuous participation in the program.

Financial Updates

COMPLETION OF A$12.5 MILLION INSTITUTIONAL OFFER AND A$6 MILLION SHARE PURCHASE PLAN

During the quarter, Radiopharm completed a A$12.5 million institutional placement and a A$3 million Share Purchase Plan (SPP) to strengthen its financial position to support the preparation and readiness to commence the RAD101 registrational Phase 3 study, the completion of RAD204 dose escalation, while progressing RAD202, RAD402 and RV01 therapeutic programs and supporting ongoing strategic partnering initiatives.

R&D TAX REFUND

In July, Radiopharm received its research and development (R&D) tax refund for the 2025 financial year, totaling to A$5,885,131, including A$104,475 interest. The refund is received as part of the Australian Government’s R&D tax incentive, which provides companies engaging in appropriate and eligible activities with a refundable tax offset of up to 43.5%.

R&D ADVANCE

Subsequent to 30 September, Radiopharm received $8,000,000 from Rockford Capital under a funding facility secured against Radiopharm’s anticipated FY26 Research and Development Tax Incentive (RDTI).

QUARTERLY RESULTS

Closing cash at the end of the quarter was $7.5 million, increasing from $4.1 million at the end of the prior quarter. Net cash outflows from operating activities during the period was $10.7 million with direct Research and Development expenditure and staff costs accounting for 93% of the operating expenditure for the quarter, excluding receipt of the R&D tax refund.

In compliance with Listing Rule 4.7C, payments to related parties and their associates, as detailed in item 6.1 of Appendix 4C, encompass remuneration for director fees to executive and non-executive directors, conducted in the ordinary course of business at commercial rates, excluding reimbursements for out-of-pocket expenses.

About Radiopharm Theranostics

Radiopharm Theranostics is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. Radiopharm is listed on ASX (RAD) and on NASDAQ (RADX). The company has a pipeline of distinct and highly differentiated platform technologies spanning peptides, small molecules and monoclonal antibodies for use in cancer. The clinical program includes one Phase 2 and five Phase 1 trials in a variety of solid tumor cancers including lung, breast, and brain metastases. Learn more at radiopharmtheranostics.com.

Authorized on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper.

For more information:

Investors:
Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Anne Marie Fields
Precision AQ (formerly Stern IR)
E: annemarie.fields@precisionaq.com

Media:
Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:
Website – https://radiopharmtheranostics.com/
X – https://x.com/TeamRadiopharm
LinkedIn – https://www.linkedin.com/company/radiopharm-theranostics/
Investor Hub – https://investorhub.radiopharmtheranostics.com/

ASML reports transactions under its current share buyback program

VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML’s current share buyback program.

Date	Total repurchased shares	Weighted average price	Total repurchased value
26-Oct-26	71,400	€1,426.90	€101,880,589
27-Oct-26	69,200	€1,449.09	€100,277,243
28-Oct-26	67,200	€1,488.08	€99,998,795
29-Oct-26	68,000	€1,493.54	€101,560,856
30-Oct-26	70,400	€1,424.96	€100,316,966

ASML’s current share buyback program was announced on 28 January 2026. Further details are available on our website.

This regular update of the transactions conducted under the buyback program is to be made public under the Market Abuse Regulation (Nr. 596/2014).

About ASML

ASML is a leading supplier to the semiconductor industry. The company provides chipmakers with hardware, software and services to mass produce the patterns of integrated circuits (microchips). Together with its partners, ASML drives the advancement of more affordable, more powerful, more energy-efficient microchips. ASML enables groundbreaking technology to solve some of humanity’s toughest challenges, such as in healthcare, energy use and conservation, mobility and agriculture. ASML is a multinational company headquartered in Veldhoven, the Netherlands, with offices across EMEA, the US and Asia. Every day, ASML’s more than 44,100 employees (FTE) challenge the status quo and push technology to new limits. ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. Discover ASML – our products, technology and career opportunities – at www.asml.com.

Media Relations contacts Monique Mols, phone +31 6 528 444 18

Investor Relations contacts Jim Kavanagh, phone +31 40 268 3938 Pete Convertito, phone +1 203 919 1714 Peter Cheang, phone +886 3 659 6771